These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1487677)

  • 1. A modeled time-varying density function for the incubation period of AIDS.
    Artzrouni M
    J Math Biol; 1992; 31(1):73-99. PubMed ID: 1487677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonparametric estimation of the incubation period of AIDS based on a prevalent cohort with unknown infection times.
    Bacchetti P; Jewell NP
    Biometrics; 1991 Sep; 47(3):947-60. PubMed ID: 1742448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of antiviral therapy on the natural history of HIV infection.
    Phillips AN; Keenlyside R; Johnson AM
    J Acquir Immune Defic Syndr (1988); 1992 Oct; 5(10):1065-6. PubMed ID: 1453323
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of backcalculation for estimation of the probability of progression from HIV infection to AIDS.
    Marion SA; Schechter MT
    Stat Med; 1993 Apr; 12(7):617-31. PubMed ID: 8511439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the incubation period of AIDS lengthening?
    Taylor JM; Kuo JM; Detels R
    J Acquir Immune Defic Syndr (1988); 1991; 4(1):69-75. PubMed ID: 1984058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study.
    Stein DS; Graham NM; Park LP; Hoover DR; Phair JP; Detels R; Ho M; Saah AJ
    Ann Intern Med; 1994 Jul; 121(2):100-8. PubMed ID: 8017721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.
    Langtry HD; Palmer KJ; Benfield P
    Pharmacoeconomics; 1993 Apr; 3(4):309-37. PubMed ID: 10146993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of HIV infection with zidovudine. The good use of AZT].
    Régnier B
    Rev Prat; 1991 Sep; 41(19):1801-4. PubMed ID: 1925359
    [No Abstract]   [Full Text] [Related]  

  • 9. Smoothed nonparametric back-projection of AIDS incidence data with adjustment for therapy.
    Becker NG; Motika M
    Math Biosci; 1993 Nov; 118(1):1-23. PubMed ID: 8260758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A conditional bootstrap procedure for reconstruction of the incubation period of AIDS.
    Chen G; Yang GL
    Math Biosci; 1993; 117(1-2):253-69. PubMed ID: 8400579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of plasma viremia in HIV-infected patients under AZT treatment: a two-year follow-up study.
    Ruffault A; Michelet C; Jacquelinet C; Guist'hau O; Genetet N; Bariou C; Colimon R; Cartier F
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):243-8. PubMed ID: 7788423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1.
    Anderson RM; Gupta S; May RM
    Nature; 1991 Mar; 350(6316):356-9. PubMed ID: 2008214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fertility parameters in men infected with human immunodeficiency virus.
    Krieger JN; Coombs RW; Collier AC; Koehler JK; Ross SO; Chaloupka K; Murphy VL; Corey L
    J Infect Dis; 1991 Sep; 164(3):464-9. PubMed ID: 1869837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of HIV disease progression in the era of prophylactic therapies.
    Hessol NA; Buchbinder SP
    AIDS Clin Rev; 1992; ():25-40. PubMed ID: 1606059
    [No Abstract]   [Full Text] [Related]  

  • 15. A model-based estimate of the mean incubation period for AIDS in homosexual men.
    Lui KJ; Darrow WW; Rutherford GW
    Science; 1988 Jun; 240(4857):1333-5. PubMed ID: 3163848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
    Ebert S; Gockel K; Horowitz S; Weber P; Vogelman B; Graziano F
    Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study.
    Rezza G
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 17 Suppl 1():S13-6. PubMed ID: 9586645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
    Krown SE; Aeppli D; Balfour HH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
    JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.